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SCANNED FROM THE BENCH: BUILDING
BRIDGES BETWEEN THE LAB AND BED
Carsten A. Wagner, Dominique Eladari, Johannes Loffing,
Fabiola Terzi
The Journal of Nephrology now features a new sec-
tion called “Scanned from the bench,” highlighting re-
cent findings from basic research with potential or
immediate consequences for the field of nephrology.
The editorial board of the Journal recognizes the im-
portance of basic research and its translation from
the laboratory to the clinical setting as early as possi-
ble to test its applicability for diagnosis and clinical
care. Ideally this is not just a one-way road, and clini-
cians send their responses back to the lab where new
hypotheses can be examined first in vitro or in animal
models. This dialogue between basic scientists and
physicians is critical for the future development of a-
cademic nephrology. However, beyond this immediate
application, knowledge of basic principles of physio-
logy and pathophysiology underlying renal function
and kidney disease is certainly also of prime impor-
tance for physicians when rationalizing diagnosis and
devising drugs or other treatments. It is our hope that
this section will contribute to building and strengthe-
ning the necessary bridges between laboratory scien-
ce and clinical nephrology.
REGULATION OF SYSTEMIC PHOSPHATE
HOMEOSTASIS
Body systemic phosphate (Pi) homeostasis is maintained
and regulated within narrow limits. It is the result of complex
interactions between regulated intestinal phosphate absorp-
tion from diet, distribution within the body (mainly bone and
skeletal muscle), and tightly controlled renal excretion (Fig.
1). Key molecules in these processes are a class of sodium-
dependent phosphate transporters, the SLC34 or type II
NaPi cotransporters (for reviews, see (1-3)). Two subtypes of
these transporters, NaPi-IIa and NaPi-IIc, are expressed
almost exclusively in kidney whereas in the intestine the first
and rate-limiting step in phosphate uptake from diet is
mediated by NaPi-IIb. The renal isoforms NaPi-IIa and NaPi-
IIc are localized in the brush border membrane of the proxi-
mal tubule and responsible for the reabsorption of phos-
phate from primary urine. The importance of the renal
cotransporters in urinary phosphate excretion and control of
systemic phosphate homeostasis is highlighted by the fact
that genetic ablation of NaPi-IIa in a mouse model reduces
renal phosphate reabsorption by about 70% leading to
hypophosphatemia (4). More striking is the clinical pheno-
type of patients with mutations in the SLC34A3 gene
encoding NaPi-IIc. These patients suffer from hereditary
hypophosphatemic rickets with hypercalciuria (HHRH)
caused by the massive renal phosphate wasting inducing
systemic hypophosphatemia (5, 6). The hypophosphatemia
triggers the compensatory increase in 1,25-dihydroxyvita-
min D3 (1,25(OH)2D3) levels stimulating intestinal phosphate
and also calcium absorption. The excessive calcium
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absorbed is excreted via the kidney causing nephrocalci-
nosis and nephrolithiasis. Patients suffer also from rick-
ets and osteomalacia. 
On the other hand, the sequelae of elevated systemic
phosphate levels as found in patients with renal insuffi-
ciency or end-stage renal disease requiring dialysis are
well known. The hyperphosphatemia and secondary
hyperparathyroidism induced by these conditions are a
major problem in the care of patients on dialysis and
directly associated with cardiovascular disease and
reduced life expectancy (7). Thus, in healthy subjects,
systemic phosphate levels have to be tightly controlled
by a variety of factors including dietary phosphate
intake, acid-base status and several hormones such as
parathyroid hormone (PTH), dopamine, glucocorticoids,
vitamin D3, insulin and many more. A relatively new
class of regulators has emerged over the last decade
called phosphatonins that control systemic phosphate
homeostasis and establish a direct link between bone
metabolism and mainly renal handling of phosphate (1,
8).
PHOSPHATONINS
Different molecules have been identified as phospha-
turic agents such as fibroblast growth factor 23 (FGF23),
FGF7, MEPE and sFRP4, and their potency to inhibit
renal phosphate reabsorption has been shown in vivo or
in vitro (8). Among them, FGF23 has received the most
attention due to the fact that this factor has established
itself as a very potent regulator of systemic phosphate
transport and balance on the level of the bone, intestine
and kidney thereby fulfilling the criteria for a “master
regulator” of phosphate homeostasis. The biological
significance of FGF23 has been established mainly
through genetic studies of patients with inherited and
acquired forms of disturbances of phosphate homeosta-
sis and subsequently confirmed in various mouse mod-
els. The picture that emerges is that FGF23 down-regu-
lates renal and intestinal phosphate (re)absorption
directly by acting on the expression of the renal and
intestinal phosphate cotransporters. Simultaneously,
FGF23 inhibits the compensatory up-regulation of the
renal 1a-hydroxylase enzyme necessary for the final
conversion of the inact ive 25-hydroxyvitamin D3
(25(OH)D3) to the active 1,25(OH)2D3 form. FGF23 is
synthesized mainly by bone cells, and its synthesis and
release is increased when serum phosphate levels rise
(Fig. 1). Thus, FGF23 is ideally suited to keep serum
phosphate levels low and to act as a bone phosphate
sensor controlling intestinal and renal phosphate han-
dling. However, FGF23 itself needs to be regulated to
adapt its expression and function. Again, genetic stud-
ies in humans and mice have shed light on these regula-
tory processes. Four recent papers address questions
related to the important issue of how bone and kidney
interact in regulating phosphate homeostasis and which
role FGF23 plays (9-12). 
Fig. 1 - Hormonal regulation of serum phosphate by parathy-
roid hormone, vitamin D3 and FGF23. Serum phosphate
levels are influenced by dietary intake and intestinal absorp-
tion, the rate of renal excretion or reabsorption, respectively,
and skeletal deposition and release from bone. Changes in
serum phosphate concentration alter the calcium × pho-
sphate product, and a fall in free calcium triggers release of
parathyroid hormone (PTH). PTH inhibits renal phosphate
reabsorption and at the same time stimulates 1a-hydroxylase
expression and activation of 1,25(OH)2D3 from its inactive
precursor 25(OH)D3. The active vitamin D3 stimulates in turn
renal and intestinal phosphate absorption as well as deposi-
tion of phosphate in bone. An increase of serum phosphate
concentrations also directly increases FGF23 synthesis and
release from bone independent from the PTH axis. FGF23
lowers phosphate concentrations by inhibiting renal and
intestinal phosphate transport as well as preventing activa-
tion of 1,25(OH2)D3 which in turn controls levels of bone
synthesis of FGF23.
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DMP1 - A NOVEL PLAYER IN THE FGF23 
PATHWAY
Feng et al and Lorenz-Depiereux et al report, in 2 indepen-
dent studies in the November issue of Nature Genetics, on
a novel monogenic disease, autosomal recessive
hypophosphatemic rickets (ARHR), affecting the systemic
regulation of phosphate homeostasis that is reminiscent of
X-linked hypophosphatemia (XLH) and autosomal domi-
nant hypophosphatemic rickets (ADHR) which are caused
by mutations either in FGF23 (causing its resistance to
degradation) or the PHEX gene that is linked to the
degradative pathway of FGF23. However, the new families
of patients showed no mutations in these genes, the family
trees indicated an autosomal recessive transmission (in
contrast to XLH and ADHR) and urinary calcium excretion
was normal (unlike in NaPi-IIc mutations). Taken together,
this evidence suggested a novel gene. Consequently,
mutations in the dentin matrix protein 1 (DMP1) were iden-
tified (11, 12). Patients present with hypophosphatemia,
rickets or osteomalacia, inappropriately normal
1,25(OH)2D3 levels, normal PTH and normal urinary calci-
um excretion (11, 12). DMP1 is widely expressed but par-
ticularly abundant in bone where it is synthesized by
osteoblasts. Feng and colleagues observed that the bone
of patients with DMP1 mutations showed a higher abun-
dance of immature osteoid deposits, suggesting a defec-
tive transition from osteoblasts to the mature osteocytes.
Using a DMP1-deficient mouse model with similar features
to those of patients, the role of DMP1 in bone biology and
systemic phosphate homeostasis was further explored.
First, DMP1-deficient mice displayed highly elevated levels
of FGF23 in bone and serum. A similar tendency to higher
FGF23 levels had also been observed in ARHR patients.
The high level of FGF23 was associated with renal phos-
phate wasting and caused hypophosphatemia. Moreover,
DMP1 mice showed abnormal maturation of osteoblasts to
osteocytes and an altered ultrastructure of bone.
Interestingly, these defects were only partially resolved by
a high-phosphate diet which restored systemic phosphate
levels but did not fully reverse the bone phenotype, indi-
cating that DMP1 may play an additional role in osteoblast
biology beyond the regulation of phosphate homeostasis.
Thus, DMP1 may play a dual role in phosphate homeosta-
sis as a negative regulator of FGF23 as well as a direct reg-
ulator of osteoblast maturation. The latter point is influ-
enced both by systemic serum phosphate levels as well as
by the local action of DMP1 through unknown pathways. 
LINKING AGING AND PHOSPHATE
HOMEOSTASIS VIA KLOTHO
What is the nature of the FGF23 receptor? It had been
unclear how FGF23 could exert its effects on phosphate
homeostasis, as no specific FGF23 receptor had been
identified to date, and experiments from cell culture indi-
cated that FGF23 required an unknown cofactor for induc-
ing its biological functions. A first idea came from genetic
studies in patients with osteoglophonic dysplasia showing
that these patients had mutations in fibroblast growth fac-
tor receptor 1 (FGFR1). Independent studies on a knock-
out mouse model with typical signs of premature aging
including hyperphosphatemia implicated a novel gene
named klotho in the regulation of phosphate homeostasis
and particularly the actions of FGF23. Urakawa et al (9)
have now identified klotho as the FGF23 cofactor and
shown that klotho binds to FGF23 and thereby enables
the complex to interact with high affinity with FGFR1(IIIc).
Moreover, neutralization of circulating klotho by injecting
anti-klotho antibodies in normal mice abolished FGF23
function, strongly suggesting that klotho is essential for
FGF23 function. Thus, this work closes the gap between
FGF23 release and its biological effects by identifying
klotho as a critical cofactor and demonstrating that the
FGFR1(IIIc) is the biological receptor for the FGF23-klotho
complex. Interestingly, expression of klotho itself appears
to be highly regulated by various factors, among them
dietary phosphate intake and vitamin D3 status.  
A VITAMIN D3 FEEDBACK LOOP
REGULATES FGF23
Each regulatory system requires feedback mechanisms
that prevent excessive reactions and allow for the integra-
tion of various stimuli. FGF23 exerts some of its effects on
phosphate homeostasis via regulation of 1,25(OH)2D3 syn-
thesis through repression of the final activation step
requiring the 1a-hydroxylase enzyme in the kidney (Fig. 2).
Selective genetic inactivation of the vitamin D3 receptor
(VDR) in chondrocytes recently provided new insights into
a potential feedback loop. Carmeliet and coworkers (10)
noted that in these animals, systemic phosphate and vita-
min D3 levels were elevated. They found that loss of the
VDR in chondrocytes reduced expression of FGF23 in
osteoblasts, relieving repression of 1a-hydroxylase in kid-
ney and thereby increasing 1,25(OH)2D3 and subsequently
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expression of the renal phosphate cotransporter NaPi-IIa. 
Taken together, these studies provide exciting new
insights into the complex regulation of systemic phos-
phate balance, underline the major role of the kidney in
the short- and long-term maintenance of body phosphate
and highlight the importance of the bone-kidney axis and
its cross-talk in regulating skeleton growth and stability.
FGF23 synthesis, release and interaction with its receptor
allow for the integration of various inputs on different lev-
els: in the bone through cross-talk between different types
of cells sensing the metabolic and developmental status
of the skeleton, in the kidney and intestine by different
hormones that regulate expression and activity of phos-
phate transporters.  Many questions have remained open,
such as how FGF23 and the other players in this regulato-
ry loop actually sense phosphate. Clinically, FGF23 levels
may be a new and useful predictor in patients with chronic
kidney disease (CKD) helping to predict the extent of
hyperphosphatemia and secondary hyperparathyroidism.
Indeed, a number of studies have shown that FGF23 is
elevated in CKD patients and correlates with PTH-resis-
tant hyperphosphatemia and vitamin D3 status. It remains
to be clarified if FGF23 will be a good predictor of hyper-
phosphatemia and its consequences or may even provide
a novel target for pharmaceutical intervention. 
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Fig. 2 - Regulation and function of FGF23. FGF23 is released
from bone upon elevated serum phosphate levels. To be bio-
logically active, FGF23 requires O-glycosylation by GALNT3
(UDP-N-acetyl-a-D-galactosamine:polypeptide N-acetylga-
lactosaminyltransferase 3). FGF23 lowers serum phosphate
levels by decreasing the expression of renal (NaPi-IIa and
NaPi-IIc) and intestinal (NaPi-IIb) phosphate transporters
thereby reducing phosphate uptake from diet and increasing
renal excretion of phosphate. Furthermore, FGF23 inhibits
1a-hydroxylase expression in kidney reducing the final step
in vitamin D3 activation and thereby prevents a compensa-
tory increase in intestinal and renal phosphate transport.
High vitamin D3 levels itself may also directly stimulate
FGF23 synthesis providing for a regulatory circuit and feed-
back mechanism. FGF23 is cleaved and inactivated by subti-
lisin-like proprotein convertases requiring a recognition motif
consisting of RXXR at position 176. PHEX is not directly
involved in FGF23 degradation but may indirectly contribute
to cleavage.
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